Table 1.
Patient characteristics and treatment outcomes
| Responders | ||||
| Patient ID | RECIST at Week 12 | Baseline LDH (U/L) | PFS (months)a | OS (months)a |
| G1 | PR | 167 | Response ongoing | Alive |
| G2 | PR | 215 | Response ongoing | Alive |
| G3 | PR | 159 | Response ongoing | Alive |
| G4 | PR | 217 | Response ongoing | Alive |
| G5 | PR | 185 | Response ongoing | Alive |
| G6 | PR | 206 | Response ongoing | Alive |
| G7 | PR | 268 | Response ongoing | Alive |
| G8 | PR | 167 | Response ongoing | Alive |
| G9 | PR | 227 | Response ongoing | Alive |
| G10 | PR | 187 | Response ongoing | Alive |
| G11 | PR | 140 | Response ongoing | Alive |
| G12 | CR | 150 | Response ongoing | Alive |
| Non-responders | ||||
| Patient ID | RECIST at Week 12 | Baseline LDH (U/L) | PFS (months)a | OS (months)a |
| P1 | PD | 303 | 2.7 | 5.8 |
| P2 | PD | 568 | 2.7 | 5.1 |
| P3 | PD | 329 | 2.7 | 3.1 |
| P4 | PD | 300 | 1.1 | Alive |
| P5 | PD | 271 | 0.5 | Alive |
| P6 | PD | 267 | 2.7 | Alive |
| P7 | PD | 169 | 2.8 | Alive |
| P8 | SD | 226 | 4 | Alive |
| P9 | SD | 269 | 4.1 | Alive |
| P10 | SD | 176 | 2.7 | 21.7 |
| P11 | SD | 195 | Response ongoing | Alive |
| P12 | SD | 402 | 5.5 | 8.3 |
Abbreviations: PR partial response, SD stable disease, PD progressive disease, CR complete response, LDH lactate dehydrogenase, PFS progression free survival, OS overall survival, U/L units per liter
aData cut off on 30th April, 2017. 11 out of 24 patients had progressed at time of analysis, all of whom were in the non-responders group. Median follow-up for these patients is 24.3 months. Normal range of LDH is 120–250 U/L